Physician profile
Salli Tazuke
NPI 1497843742
$8,373.02
in general payments reported to CMS, 2019-2025
6 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $60.61 · 2021: $149 · 2022: $6,881 · 2023: $241 · 2024: $613 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.57 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $7,024.73 | 2019-2025 | Menopur |
| Emd Serono, INC. | $640.32 | 2019-2024 | |
| Organon LLC | $595.12 | 2021-2025 | Follistim Aq, Ganirelix Acetate, Nexplanon |
| Merck Sharp & Dohme LLC | $73.76 | 2019-2021 | |
| Minerva Surgical, INC | $21.65 | 2024 | |
| Pfizer INC. | $17.44 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salli Tazuke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.